- Home
- PC vs CANF Comparison
PC vs CANF Comparison
Compare PC & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PC
- CANF
- Stock Information
- Founded
- PC 2012
- CANF 1994
- Country
- PC Singapore
- CANF Israel
- Employees
- PC N/A
- CANF N/A
- Industry
- PC Restaurants
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- PC Consumer Discretionary
- CANF Health Care
- Exchange
- PC Nasdaq
- CANF Nasdaq
- Market Cap
- PC 12.4M
- CANF 9.6M
- IPO Year
- PC 2024
- CANF N/A
- Fundamental
- Price
- PC $6.82
- CANF $0.63
- Analyst Decision
- PC
- CANF Strong Buy
- Analyst Count
- PC 0
- CANF 2
- Target Price
- PC N/A
- CANF $14.00
- AVG Volume (30 Days)
- PC 80.2K
- CANF 140.0K
- Earning Date
- PC 01-01-0001
- CANF 08-26-2025
- Dividend Yield
- PC N/A
- CANF N/A
- EPS Growth
- PC N/A
- CANF N/A
- EPS
- PC N/A
- CANF N/A
- Revenue
- PC $3,345,964.00
- CANF $560,000.00
- Revenue This Year
- PC N/A
- CANF $461.72
- Revenue Next Year
- PC N/A
- CANF N/A
- P/E Ratio
- PC N/A
- CANF N/A
- Revenue Growth
- PC N/A
- CANF N/A
- 52 Week Low
- PC $5.11
- CANF $0.63
- 52 Week High
- PC $51.57
- CANF $3.12
- Technical
- Relative Strength Index (RSI)
- PC 50.24
- CANF 29.23
- Support Level
- PC $6.13
- CANF $0.64
- Resistance Level
- PC $7.03
- CANF $0.68
- Average True Range (ATR)
- PC 0.73
- CANF 0.03
- MACD
- PC 0.01
- CANF 0.01
- Stochastic Oscillator
- PC 64.25
- CANF 2.00
About PC Premium Catering (Holdings) Limited Ordinary Shares
Premium Catering (Holdings) Ltd is a company that conducts its operations through its subsidiary is mainly engaged in food catering for functions, events, and workers in Singapore. Are specialized in Indian, Bangladesh, and Chinese cuisine and all its food products are Halal food which is permissible for consumption by Muslims to consume. Are an ACRA registered company and licensed by SFA to operate and process food business. Serve highquality value-packed food, company deliver's a reliable and dependable service to meet customer's daily meal requirements. The Company recognizes revenue from sales of budgeted prepared meals.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).